RE: Business-News-Today.com14 Apr 2026 12:43
Value of Avacta IP still not recognised : Waiting game required
exciting times ahead .
Gmcc
-----------
"How is the market currently pricing AVCT relative to comparable oncology platform deals in the XDC space?
Avacta closed on 9 April 2026 at 70p, with a market capitalisation of approximately £309 million and 453 million shares in issue. The 52-week range runs from 26p to 82.5p, and the stock has outperformed the FTSE All Share by approximately 39% over the past year. The analyst consensus target sits at 71.33p, fractionally above the then-prevailing price, though the high estimate of 106p reflects the asymmetric upside case being made by the more bullish voices covering the stock.
The disconnect argument made most forcefully in retail investor forums rests on the Tubulis and Gilead comparison. Forum participants have drawn attention to the fact that Gilead’s deal with Tubulis, a clinical-stage ADC platform with two clinical assets, was structured with up to £5 billion in potential value, and that Avacta’s pre|CISION platform, with a clinically validated delivery mechanism, three programme generations, and a FAP-based cleavage system covering roughly 90% of solid tumour types, sits at a fraction of that valuation on AIM. The counterargument is that Avacta’s programmes remain early-stage, that the AVA6103 human pharmacokinetic data has not yet been generated, and that platform valuation premiums in oncology are awarded on clinical proof-of-concept, not preclinical superiority alone."
Analysts note that financial constraints and the absence of confirmed partnering agreements remain the key risks flagging on current assessments of the stock. The market is, in effect, pricing in meaningful clinical progress but discounting the platform ceiling until human data from FOCUS-01 is in hand."
Sign In
Follow the stocks
